Specific Targeting MRI of Chitosan Oligosaccharide Modified Fe3O4 Nanoprobe on Macrophage and the Inhibition of Macrophage Foaming Induced by ox-LDL

Source:
By:Cao Xu, Ma Ke, hao Yu Tao, yang De Xi, yu Fang Hu, jing Jing Li

DOI: https://doi.org/10.30564/jams.v4i2.3039

Abstract: Atherosclerosis (AS) is a primary cause of morbidity and mortality all over the world. Molecular imaging techniques can enable early localization and diagnosis of atherosclerosis plaques. Recent newly developed chitooligosaccharides (CSO) is considered to be capable of target mannose receptors on the surface of macrophages and to inhibit foam cell formation. Here we present a targeting magnetic resonance imaging (MRI) nanoprobe, which was successfully constructed with polyacrylic acid (PAA) modified nanometer iron oxide (Fe3O4) as the core, and coating with CSO molecules, possessing the abilities of targeted MRI and specifically inhibition of the formation of foamy macrophages in the atherosclerotic process. The experimental results showed that the distributions of PAA-Fe3O4 and CSO-PAA-Fe3O4 were uniform and the corresponding sizes were about 5.93 nm and 8.15 nm, respectively. The Fourier transform infrared spectra (FTIR) testified the CSO was coupled with PAA-Fe3O4 successfully. After coupled with CSO, the r1 of PAA-Fe3O4 was increased from 5.317 mM s-1 to 6.147 mM s-1, indicating their potential as MRI contrast agent. Oil Red O staining and total cholesterols (TC) determination showed that CSO-PAA-Fe3O4 could significantly inhibit the foaming process of RAW264.7 cells induced by oxidatively modified low density lipoprotein (ox-LDL). In vitro cellular MRI displayed that, compared with PAA-Fe3O4,CSO-PAA-Fe3O4 could lower the T1 relaxation time of RAW264.7 cells better. In summary, construction of CSO-PAA-Fe3O4 nanoprobe in this study could realize the targeted MRI of macrophages and inhibition of ox-LDL induced macrophage foaming process. This will provide a new avenue in the diagnosis and treatment of AS. References:

[1] Adamson PD, Newby DE, Dweck MR(2016)Translational Coronary Atherosclerosis Imaging withPET.CARDIOL CLIN 34 (1):179-186. DOI: 10.1016/j.ccl.2015.06.002. [2] Huang Y, Coman D, Hyder F, Ali MM(2015)Dendrimer- Based Responsive MRI Contrast Agents (G1-G4) for Biosensor Imaging of Redundant Deviation in Shifts (BIRDS).Bioconjug Chem 26 (12):2315-2323. DOI: 10.1021/acs.bioconjchem.5b00568. [3] Ibañez B, Badimon JJ, Garcia MJ(2009)Diagnosis of atherosclerosis by imaging.AM J MED 122 (1 SupFigure pl):S15 S25. DOI: 10.1016/j.amjmed.2008.10.014. [4] Cheng D, Wang Y, Liu X, Pretorius PH, Liang M, Rusckowski M, Hnatowich DJ(2010)Comparison of 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice.Bioconjug Chem 21 (8):1565-1570. DOI: 10.1021/bc1001467. [5] Hyafil F, Schindler A, Sepp D, Obenhuber T, Bayer-Karpinska A, Boeckh-Behrens T, Höhn S, Hacker M, Nekolla SG, Rominger A, Dichgans M, Schwaiger M, Saam T, Poppert H(2016)High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging.Eur J Nucl Med Mol Imaging 43 (2):270-279. DOI: 10.1007/s00259-015-3201-8. [6] Vaidyanathan K, Gopalakrishnan S(2017)Nanomedicine in the Diagnosis and Treatment of Atherosclerosis- A Systematic Review.Cardiovasc Hematol Disord Drug Targets 17 (2):119-131. DOI: 10.2174/1871529X17666170918142653. [7] Roy TL, Forbes TL, Dueck AD, Wright GA(2018)MRI for peripheral artery disease: Introductory physics for vascular physicians.VASC MED 23 (2):153-162. DOI: 10.1177/1358863X18759826. [8] Cromer BS, Kshitiz, Wang CJ, Orukari I, Levchenko A, Bulte JW, Walczak P(2013)Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis.MAGN RESON MED 69 (1):255-262. DOI: 10.1002/mrm.24216. [9] Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, Forrest EK, Bienek C, Mills NL, Burdess A, Dhaliwal K, Simpson AJ, Wallace WA, Hill AT, Roddie PH, McKillop G, Connolly TA, Feuerstein GZ, Barclay GR, Turner ML, Newby DE(2012)In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans.Circ Cardiovasc Imaging 5 (4):509-517. DOI: 10.1161/CIRCIMAGING.112.972596. [10] Ramaswamy S, Schornack PA, Smelko AG, Boronyak SM, Ivanova J, Mayer JJ, Sacks MS(2012)Superparamagnetic iron oxide (SPIO) labeling efficiency and subsequent MRI tracking of native cell populations pertinent to pulmonary heart valve tissue engineering studies.NMR BIOMED 25 (3):410-417. DOI: 10.1002/nbm.1642. [11] Gneveckow U, Jordan A, Scholz R, Brüss V, Waldöfner N, Ricke J, Feussner A, Hildebrandt B, Rau B, Wust P(2004)Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia.MED PHYS 31 (6):1444-1451. DOI: 10.1118/1.1748629. [12] Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerth EW, Chen ZG, Platt S(2012)Magnetic nanoparticle- based hyperthermia for head & neck cancer in mouse models.THERANOSTICS 2 (1):113-121. DOI: 10.7150/thno.3854. [13] Hyung JH, Ahn CB, Il KB, Kim K, Je JY(2016)Involvement of Nrf2-mediated heme oxygenase-1 expression in anti-inflammatory action of chitosan oligosaccharides through MAPK activation in murine macrophages.EUR J PHARMACOL 793:43-48. DOI: 10.1016/j.ejphar.2016.11.002. [14] Estelrich J, Sánchez-Martín MJ, Busquets MA(2015)Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents.Int J Nanomedicine 10:1727-1741. DOI: 10.2147/IJN.S76501. [15] Khandhar AP, Wilson GJ, Kaul MG, Salamon J, Jung C, Krishnan KM(2018)Evaluating size-dependent relaxivity of PEGylated-USPIOs to develop gadolinium- free T1 contrast agents for vascular imaging.J BIOMED MATER RES A 106 (9):2440-2447. DOI: 10.1002/jbm.a.36438. [16] Te BB, van Tilborg GA, Strijkers GJ, Nicolay K(2012)Molecular MRI of Inflammation in Atherosclerosis. Curr Cardiovasc Imaging Rep 5 (1):60-68. DOI: 10.1007/s12410-011-9114-4. [17] Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, Calabró D, Avallone B, Balsamo G(1994)Chitosan- mediated stimulation of macrophage function.BIOMATERIALS 15 (15):1215-1220. DOI: 10.1016/0142-9612(94)90272-0. [18] Hu Z, Shi X, Yu B, Li N, Huang Y, He Y(2018)Structural Insights into the pH-Dependent Conformational Change and Collagen Recognition of the Human Mannose Receptor.STRUCTURE 26 (1):60-71. DOI: 10.1016/j.str.2017.11.006. [19] Hou LN, Zhao LH(2006)Binding and stimulatory effect of oligochitosan in macrophages.Journal of China Medical University 35 (2):124-127. DOI: 10.3969/j.issn.0258-4646.2006.02.006. [20] Xiang, D(2018)mechanism of chitosan oligosaccllarides inhibiting foam cells formation via autophagy. MA Dissertation, Southwest Medical University. [21] Jafari H, Bernaerts KV, Dodi G, Shavandi A(2020)Chitooligosaccharides for wound healing biomaterials engineering.Mater Sci Eng C Mater Biol Appl 117:111266. DOI: 10.1016/j.msec.2020.111266. [22] Xu Q, Dou J, Wei P(2008)Chitooligosaccharides induce apoptosis of human hepatocellular carcinoma cells via up regulation of Bax.Carbohydrate Polymers: Scientific and Technological Aspects of Industrially Important Polysaccharides 71 (4):509-514. [23] Dou J, Du Y, Tan C(2007)Effects of chitooligosaccharides on rabbit neutrophils in vitro.Carbohydrate Polymers: Scientific and Technological Aspects of Industrially Important Polysaccharides 69 (2):209-213. [24] Liaqat F, Eltem R(2018)Chitooligosaccharides and their biological activities: A comprehensive review.Carbohydr Polym 184:243-259. DOI: 10.1016/j.carbpol.2017.12.067. [25] Kucheryavy P, He J, John VT, Maharjan P, Spinu L, Goloverda GZ, Kolesnichenko VL(2013)Superparamagnetic iron oxide nanoparticles with variable size and an iron oxidation state as prospective imaging agents.LANGMUIR 29 (2):710-716. DOI: 10.1021/la3037007. [26] Su YJ, Zhao Q, Sun JZ(2012)Synthesis and Characterization of Chitosan Oligosaccharide-graft-Acrylic Acid Biodegradable Crosslinker.Journal of Chemical Engineering of Chinese Universities 26 (2):285-289. DOI: 10.3969/j.issn.1003-9015.2012.02.017.